Brief: Nanobiotix amends global licensing agreement for JNJ-1900 (NBTXR3)
17/03/2025 21:17
March 17 (Reuters) - Nanobiotix SA NANOB.PA: NANOBIOTIX STRENGTHENS FINANCIAL POSITION THROUGH AMENDMENT OF GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) AND EXTENDS CASH VISIBILITY TO MID-2026 NANOBIOTIX SA - AMENDS LICENSING AGREEMENT WITH JOHNSON & JOHNSON NANOBIOTIX SA - JOHNSON & JOHNSON TO COVER MOST COSTS FOR NANORAY-312 TRIAL NANOBIOTIX SA - DEAL VALUE ADJUSTED FROM $2.7B TO $2.6B NANOBIOTIX SA - REVISIONS TO FUTURE MILESTONE PAYMENTS TOTAL $105M NANOBIOTIX SA - POTENTIAL ADDITIONAL MILESTONES OF $650M FOR FIVE NEW INDICATIONS NANOBIOTIX SA: AMENDED AGREEMENT ENABLED NANOBIOTIX TO STRENGTHEN FINANCIAL POSITION, EXTENDING CASH VISIBILITY TO MID-2026 Source text: ID:nGNX4N88Cp Further company coverage: NANOB.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering